Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Pennsylvania |
---|---|
Information provided by: | University of Pennsylvania |
ClinicalTrials.gov Identifier: | NCT00598923 |
Our hypothesis is that topiramate will reduce acute seizures after traumatic brain injury and will help prevent the development of epilepsy after traumatic brain injury.
Condition | Intervention | Phase |
---|---|---|
Traumatic Brain Injury Epilepsy |
Drug: topiramate Drug: phenytoin |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Active Control, Parallel Assignment |
Official Title: | Preventing Epilepsy After Traumatic Brain Injury: A Pilot, Single-Center Randomized Trial of Topiramate to Prevent Seizures After Moderate to Severe TBI |
Estimated Enrollment: | 90 |
Study Start Date: | November 2004 |
Estimated Study Completion Date: | February 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Phenytoin 20mg/kg load, then Topiramate, 100 mg twice daily, starting at 24 hours post-TBI for 6 days.
|
Drug: topiramate
100 twice per day for 6 days after loading dose of phenytoin
|
2: Experimental
topiramate for 3 months after loading dose of phenytoin
|
Drug: topiramate
100 mg twice per day for 3 months
|
3: Placebo Comparator
Phenytoin 20 mg/kg as loading dose than 300 mg/day for total of 7 days
|
Drug: phenytoin
loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
|
Traumatic brain injury (TBI) causes epilepsy in up to 30% of civilian and 50% of military head injuries, exacerbating chronic neurological disability. There is currently no method for preventing epilepsy after TBI. We hypothesize that the new antiepileptic drug, topiramate (TPM), will (1) reduce acute seizures and prevent the development of epilepsy following TBI and (2) improve neurological recovery. We propose to perform a pilot clinical trial to develop the necessary infrastructure for larger scale randomized clinical trials to test TPM, and, possibly, other new antiepileptic drugs with neuroprotective properties, for their ability to prevent epilepsy after TBI. Subjects with TBI will be randomized within 24 hours to one of three groups: 1) TPM for one week, 2) TPM for three months, or 3) phenytoin for one week. Subjects will be followed for two years for the development of seizures and for neurological outcome. Serial EEGs and MRIs will be performed to explore potential mechanisms for the development of epilepsy after TBI. These new tools for the clinical study of epilepsy prevention, and neuroprotection in general, will be developed that can be applied to a wide variety of studies and which will facilitate future research in this critical area.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Irreversibly fatal TBI
Contact: Kelly S Maxwell | 215 614 0520 | kelly.maxwell@uphs.upenn.edu |
United States, Pennsylvania | |
Hospital of the University of Pennsylvania | Recruiting |
Philadelphia, Pennsylvania, United States, 19104 | |
Principal Investigator: Marc A Dichter, MD, PhD | |
Sub-Investigator: Susan T Herman, MD |
Principal Investigator: | Marc A Dichter, MD, PhD | University of Pennsylvania |
Responsible Party: | University of Pennsylvania ( Dr. Marc A. Dichter ) |
Study ID Numbers: | PR043514 |
Study First Received: | January 11, 2008 |
Last Updated: | January 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00598923 |
Health Authority: | United States: Food and Drug Administration |
tbi traumatic brain injury epilepsy |
Craniocerebral Trauma Phenytoin Epilepsy Seizures Wounds and Injuries Topiramate |
Disorders of Environmental Origin Central Nervous System Diseases Trauma, Nervous System Brain Diseases Brain Injuries |
Anti-Obesity Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases Protective Agents |
Neuroprotective Agents Central Nervous System Agents Pharmacologic Actions Anticonvulsants |